Sintilimab
- Generic Name
- Sintilimab
- Drug Type
- Biotech
- CAS Number
- 2072873-06-2
- Unique Ingredient Identifier
- 8FU7FQ8UPK
Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- First Affiliated Hospital of Guangxi Medical University
- Target Recruit Count
- 150
- Registration Number
- NCT06680115
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT
Phase 2
Recruiting
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- Radiation: stereotactic body radiation therapy (SBRT)
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT06664996
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC
Phase 2
Not yet recruiting
- Conditions
- Colon CancerRectal Cancer
- Interventions
- Drug: Ultrafractionated RT and CGA Guided systemic treatment.Other: data prospectively collectedRadiation: Ultrafractionated Radiotherapy
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 124
- Registration Number
- NCT06652412
Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
Phase 2
Not yet recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 296
- Registration Number
- NCT06620822
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
Phase 3
Recruiting
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 590
- Registration Number
- NCT06618664
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
Surgery for Ovarian Cancer After PARPi Therapy in Precision
Phase 1
Not yet recruiting
- Conditions
- Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
- Interventions
- Procedure: surgery/chemotherapy
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Shanghai Gynecologic Oncology Group
- Target Recruit Count
- 33
- Registration Number
- NCT06602063
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, China
🇨🇳Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer
Phase 3
Recruiting
- Conditions
- Advanced Endometrial Cancer
- Interventions
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Hutchmed
- Target Recruit Count
- 412
- Registration Number
- NCT06584032
- Locations
- 🇨🇳
Beijing Obstetrics and Gynecology Hospital, Beijing, Beijing, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chongqing, China
Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma
Phase 2
Recruiting
- Conditions
- Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
- Interventions
- Drug: P-GEMOX Regimen
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 84
- Registration Number
- NCT06583083
- Locations
- 🇨🇳
Sun Yat-sen Universitiy Cancer Center, Guangzhou, Guangdong, China
A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy Concurrent With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer
Phase 2
Not yet recruiting
- Conditions
- Advanced Solid TumorRectal Cancer
- Interventions
- Radiation: Short-course radiotherapy
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-08-29
- Target Recruit Count
- 35
- Registration Number
- NCT06577194
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
Phase 1
Recruiting
- Conditions
- Pancreas Cancer
- Interventions
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 63
- Registration Number
- NCT06572813
- Locations
- 🇨🇳
First Affiliated Hospital of Zhejiang University Schlool of Medicine, Hangzhou, Zhejiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath